Abstract
Chronic hepatitis B infection remains a relatively common disease in European hepatology and gastroenterology practice. Current treatment guidelines in Europe discuss pegylated interferon-α or nucleoside analogues in treating chronic hepatitis B. The indications and the necessity for treatment are based mainly on the combination of three criteria: serum hepatitis B virus DNA concentrations, serum aminotransferase levels, and histologic grade and stage. The advent of potent nucleoside analogues with low rates of resistance has potentially simplified treatment. The pipeline of new agents to treat hepatitis B remains restricted, and cross-resistance is shared by several nucleosides. Thus, the guidelines emphasize the advantage and necessity of using potent agents with low rates of resistance as optimal therapy to avoid difficult-to-treat, multidrug-resistant hepatitis B.
Similar content being viewed by others
References and Recommended Reading
European Association for the Study of the Liver: EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009, 50:227–242.
Guyatt GH, Oxman AD, Kunz R, et al.: Going from evidence to recommendations. BMJ 2008, 336:1049–1051.
Guyatt GH, Oxman AD, Kunz R, et al.: What is “quality of evidence” and why is it important to clinicians? BMJ 2008, 336:995–998.
Guyatt GH, Oxman AD, Vist GE, et al.: GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008, 336:924–926.
Jaeschke R, Guyatt GH, Dellinger P, et al.: Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive. BMJ 2008, 337:a744.
Schunemann HJ, Oxman AD, Brozek J, et al.: Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ 2008, 336:1106–1110.
Rizzetto M: Viral hepatitis in the third millennium. Research in Virology 1998, 149:251–256.
Rizzetto M, Ciancio A: Chronic HBV-related liver disease. Mol Aspects Med 2008, 29:72–84.
Hadziyannis SJ, Vassilopoulos D: Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001, 34(4 Pt 1):617–624.
Hoofnagle JH, Doo E, Liang TJ, et al.: Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007, 45:1056–1075.
Martinot-Peignoux M, Boyer N, Colombat M, et al.: Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers. J Hepatol 2002, 36:543–546.
Ganem D, Prince AM: Hepatitis B virus infection—natural history and clinical consequences. N Engl J Med 2004, 350:1118–1129.
Fattovich G, Bortolotti F, Donato F: Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008, 48:335–352.
Fattovich G: Natural history and prognosis of hepatitis B. Semin Liver Dis 2003, 23:47–58.
Pawlotsky JM, Dusheiko G, Hatzakis A, et al.: Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology 2008, 134:405–415.
Ogawa E, Furusyo N, Toyoda K, et al.: Transient elastography for patients with chronic hepatitis B and C virus infection: non-invasive, quantitative assessment of liver fibrosis. Hepatol Res 2007, 37:1002–1010.
Janssen HL, van Zonneveld M, Senturk H, et al.: Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005, 365:123–129.
Lai CL, Chien RN, Leung NW, et al.: A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998, 339:61–68.
Lai CL, Gane E, Liaw YF, et al.: Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007, 357:2576–2588.
Lau GK, Piratvisuth T, Luo KX, et al.: Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005, 352:2682–2695.
Marcellin P, Chang TT, Lim SG, et al.: Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003, 348:808–816.
Heathcote EJ, Gane E, DeMan R, et al.: A randomized, double-blind, comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HbeAG positive chronic hepatitis B (CHB): study GS-US-174-0103. Hepatology 2007, 46:861A.
Chang TT, Gish RG, de Man R, et al.: A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006, 354:1001–1010.
Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al.: Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006, 131:1743–1751.
Tassopoulos NC, Volpes R, Pastore G, et al.: Efficacy of lamivudine in patients with hepatitis B e antigen-negative hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 1999, 29:889–896.
Keeffe EB, Dieterich DT, Pawlotsky JM, Benhamou Y: Chronic hepatitis B: preventing, detecting, and managing viral resistance. Clin Gastroenterol Hepatol 2008, 6:268–274.
Keeffe EB, Marcellin P: New and emerging treatment of chronic hepatitis B. Clin Gastroenterol Hepatol 2007, 5:285–294.
Marcellin P, Heathcote EJ, Buti M, et al.: Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008, 359:2442–2455.
Keeffe EB, Dieterich DT, Han SH, et al.: A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008, 6:1315–1341.
Flink HJ, van Zonneveld M, Hansen BE, et al.: Treatment with peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol 2006, 101:297–303.
Perrillo RP: Factors influencing response to interferon in chronic hepatitis B: implications for Asian and Western populations. Hepatology 1990, 12:1433–1435.
Wong DK, Cheung AM, O’Rourke K, et al.: Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993, 119:312–323.
Zoulim F: Current data on the treatment of chronic hepatitis B. Presse Med 2008, 37:287–293.
Buster EH, Schalm SW, Janssen HL: Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues. Best Pract Res Clin Gastroenterol 2008, 22:1093–1108.
Fried MW, Piratvisuth T, Lau GK, et al.: HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 2008, 47:428–434.
Perrillo RP, Lai CL, Liaw YF, et al.: Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002, 36:186–194.
Zhou XJ, Boehme RE, Chao G, et al.: HBV viral dynamics of telbivudine vs. lamivudine and the combination: relevance of early viral suppression to better long-term clinical response. J Hepatol 2005, 42:197.
Bzowej N, Lai C, Gane E, et al.: Phase III comparison of telbivudine vs lamivudine in patients with chronic hepatitis B: efficacy, safety, and predictors of response at 1 year. Gastroenterology 2006, 130:A765–A766.
Zoulim F, Durantel D, Deny P: Management and prevention of drug resistance in chronic hepatitis B. Liver Int 2009, 29(Suppl 1):108–115.
Liaw YF, Sung JJ, Chow WC, et al.: Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004, 351:1521–1531.
Davies SE, Portmann BC, O’Grady JG, et al.: Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology 1991, 13:150–157.
Grellier L, Mutimer D, Ahmed M, et al.: Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996, 348:1212–1215.
Mutimer D, Dusheiko G, Barrett C, et al.: Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: long-term follow-up. Transplantation 2000, 70:809–915.
Lenci I, Tisone G, Di Paolo D, et al.: Total and covalently closed circular DNA detection in post liver transplant liver biopsies of HBV positive patients who underwent liver transplantation with undetectable viraemia. Hepatology 2008,44:573A.
Lalazar G, Rund D, Shouval D: Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 2007, 136:699–712.
Mindikoglu AL, Regev A, Schiff ER: Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and its prevention. Clin Gastroenterol Hepatol 2006, 4:1076–1081.
Hsu C, Hsiung CA, Su LJ, et al.: A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin’s lymphoma: a randomized trial. Hepatology 2008, 47:844–853.
Lau GKK: Hepatitis B reactivation after chemotherapy: two decades of clinical research. Hepatol Int 2008, 2:152–162.
Jonas MM: Hepatitis B and pregnancy: an underestimated issue. Liver Int 2009, 29(Suppl 1):133–139.
Dieu E, Bocket L, Coursier J, et al.: Hepatitis B viral infection treated with lamivudine during pregnancy. Gastroenterol Clin Biol 2009, 33:391–393.
Peitsidou A, Peitsidis P, Michopoulos S, et al.: Exacerbation of liver cirrhosis in pregnancy: a complex emerging clinical situation. Arch Gynecol Obstet 2009, 279:911–913.
Tran TT: Management of hepatitis B in pregnancy: weighing the options. Cleve Clin J Med 2009, 76(Suppl 3):S25–S29.
Wiseman E, Fraser MA, Holden S, et al.: Perinatal transmission of hepatitis B virus: an Australian experience. Med J Aust 2009, 190:489–492.
Xu WM, Cui YT, Wang L, et al.: Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat 2009, 16:94–103.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dusheiko, G., Burney, T. Current treatment of chronic HBV infection: A European perspective. Curr hepatitis rep 8, 141–147 (2009). https://doi.org/10.1007/s11901-009-0020-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11901-009-0020-z